Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Bezafibrat----[1] 93
2Bezafibrat Genericon retard 400 mg----[1] 93
3Bezafibrate[1] Bezafibrate[1] D01366 (Name: Bezafibrate)[1] PPARA 💬[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[7] 20, 93, 94, 160, 296, 316, 324
4Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy[2] Bezafibrate,
Ursodeoxycholic acid		[2] D00734 ,
D01366 (Name: Bezafibrate)		[2] NR1H4,
PPARA 💬		[11] Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 94
5Bezafibrate (drug)[1] Bezafibrate[1] D01366 (Name: Bezafibrate)[1] PPARA 💬[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 316
6Bezafibrate (INN 3968)[1] Bezafibrate[1] D01366 (Name: Bezafibrate)[1] PPARA 💬[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 324
7Bezafibrate 200 MG[1] Bezafibrate[1] D01366 (Name: Bezafibrate)[1] PPARA 💬[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93
8Bezafibrate 200 MG Oral Tablet[1] Bezafibrate[1] D01366 (Name: Bezafibrate)[1] PPARA 💬[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93
9Bezafibrate 400 MG[1] Bezafibrate[1] D01366 (Name: Bezafibrate)[1] PPARA 💬[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93
10Bezafibrate IR[1] Bezafibrate[1] D01366 (Name: Bezafibrate)[1] PPARA 💬[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93
11Bezafibrate SR[1] Bezafibrate[1] D01366 (Name: Bezafibrate)[1] PPARA 💬[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93
12Bezafibrate, Beza, BZF, Bezalip[1] Bezafibrate[1] D01366 (Name: Bezafibrate)[1] PPARA 💬[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93
13Bezafibrate, Beza, BZF, Bezalip mono[1] Bezafibrate[1] D01366 (Name: Bezafibrate)[1] PPARA 💬[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93